SKELID
LOE ApproachingNDAORALTABLET
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKELID is an oral small-molecule tablet approved in 1997 by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, limiting assessment of therapeutic positioning.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a contracting team and shift toward generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SKELID offers limited career growth due to zero linked job postings and approaching LOE status. Roles available are primarily defensive/transition-focused rather than launch or growth-oriented, suitable for professionals with expertise in lifecycle management and generic transition strategy.
Brand ManagerField Sales Representative
Worked on SKELID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.